XIV Eurasian Hematology-Oncology Congress - EHOC 2023


 

38 views
February 16, 2024

Chapters

Combination vs Monotherapy in CLL Treatment

00:00

Survival Rates: Comparing Different CLL Therapies

01:59

MRD-Driven Therapy & High-Risk Patient Results

03:45

PFS Data for p53 & High-Risk CLL Subgroups

04:34

Maintaining MRD with Therapeutic Combinations

07:05

Evaluating Toxicity & Future of CLL Treatments

09:28

Comments 0
Login to view comments. Click here to Login